TABLE 2 | Anti-angiogenic drugs approved for clinical use and phase of clinical trials for other indications
From the following article:
Angiogenesis: an organizing principle for drug discovery?
Judah Folkman
Nature Reviews Drug Discovery 6, 273-286 (April 2007)
doi:10.1038/nrd2115
| Drug (Trade name; company) | Approved* | Phase III | Phase II | Phase I |
|---|---|---|---|---|
| Bortezomib (Velcade; Millennium Pharmaceuticals) | Multiple myeloma (2003) | NSCLC, multiple myeloma, NHL | Multiple myeloma, NHL, NSCLC, lymphoma, gliomas, melanoma, Waldenstrom's macroglobinaemia, prostate, head and neck, breast, liver, nasopharyngeal, gastric, pancreatic, colorectal, cervical/vaginal cancer, and others | Lymphoma, myelodysplasia, multiple myeloma, NHL, solid tumours, head and neck, cervical, colorectal, ovarian, prostate cancer, and others |
| Thalidomide (Thalomid; Celgene Corporation) | Multiple myeloma (2003‡) | Multiple myeloma, brain metastases, SCLC, NSCLC, prostate, kidney, ovarian, hepatocellular cancer | Soft tissue sarcoma, multiple myeloma, ALS, melanoma, neuroendocrine tumours, leukaemia, glioma, glioblastomas, paediatric neuroblastoma, NSCLC, NHL, paediatric solid tumours, myelo-fibrosis, myelodysplastic syndrome, AML, CLL, SCLC, Hodgkin's disease, paediatric brain stem, liver, colorectal, kidney, neuroendocrine, endometrial, thyroid, uterine, ovarian cancer, and others | Solid tumours, glioma |
| Bevacizumab (Avastin; Genentech) | Colorectal cancer (2004), lung cancer (2006) | NSCLC, GIST, diabetic retinopathy, vascular occlusions, retinopathy of prematurity, colorectal, breast, ovarian, peritoneal, pancreatic, prostate, kidney cancer | Glioblastoma, glioma, mesothelioma, NSCLC, AML, CLL, CML, lymphoma, angiosarcoma, melanoma, billary tumours, SCLC, Kaposi's sarcoma, sarcomas, NHL, carcinoid, oesophagogastric, gastric, renal cell, head and neck, rectal, hepatocellular, bladder, pancreatic, gall bladder, breast, neuroendocrine, cervical, ovarian, endometrial cancer, and others | NSCLC, pancreatic, solid tumours, head and neck tumours, VHL, retinal tumours |
| Erlotinib (Tarceva; Genentech, OSI Pharmaceuticals, Roche) | Lung cancer (2004) | NSCLC, colorectal, pancreatic, ovarian, head and neck, oral cancer | NSCLC, mesothelioma, glioblastoma, glioma, gall bladder, GIST, biliary tumours, bladder cancer prevention, malignant peripheral nerve sheath tumours, endometrial, colorectal, pancreatic, breast, renal cell, prostate, ovarian, head and neck, gastric/oesophageal, liver cancer, and others | NSCLC, glioblastoma, solid tumours, colorectal, pancreatic, head and neck cancer |
| Pegaptanib (Macugen; OSI Pharmaceuticals) | Age-related macular degeneration (2004) | |||
| Endostatin (Endostar) | Lung cancer (2005§) | |||
| Sorafenib (Nexavar; Onyx Pharmaceuticals) | Kidney cancer (2005) | Kidney, melanoma, hepatocellular cancer | Melanoma, glioblastoma, GIST, SCLC, thyroid, neuroendocrine, mesothelioma, soft tissue sarcoma, NSCLC, CLL, multiple myeloma, cholangiocarcinoma, NHL, kidney, colorectal, prostate, ovarian, peritoneal, pancreatic, breast, gastric, head and neck, uterine, gall bladder, bladder cancer, and others | Solid tumours, melanoma, glioblastoma, NHL, glioma, multiple myeloma, Kaposi's sarcoma, ALL, CML, MDS |
| Lenalidomide (Revlimid; Celgene Corporation) | Myelodysplastic syndrome (2005) | Multiple myeloma, myelodysplastic syndrome | NSCLC, NHL, multiple myeloma, CLL, myelofibrosis, myelodysplastic syndrome, glioblastoma, ocular melanoma, AML, mantle-cell lymphoma, Waldenstrom's macroglobinaemia, ovarian/peritoneal, thyroid, prostate cancer | Multiple myeloma, prostate cancer, melanoma, myelodysplastic syndrome, solid tumours, paediatric CNS tumours |
| Sunitinib (Sutent; Pfizer) | GIST, kidney cancer (2006) | Renal cell cancer, GIST | Melanoma, VHL/solid tumour, NSCLC, GIST, hepatocellular, colorectal, prostate, breast, renal cell, gastric, neuroendocrine cancer, and others | Melanoma, solid tumours, colorectal, breast cancer |
| Ranibizumab (Lucentis; Genentech) | Age-related macular degeneration (2006) | |||
| *Year of first approval by the US Food and Drug Administration, unless stated otherwise. | ||||
| ‡Australia, approved by US Food and Drug Administration in 2006. | ||||
| §China State Food and Drug Administration. ALS, amyotrophic lateral sclerosis (or Lou Gehrig's disease); ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; CLL, chronic lymphocytic leukaemia; CML, chronic myeloid leukaemia; CNS, central nervous system; GIST, gastrointestinal stromal tumour; MDS, myelodysplastic syndromes; NSCLC, non-small-cell lung cancer; NHL, non-Hodgkin's lymphoma; SCLC, small-cell lung cancer; VHL, von Hippel Lindau. | ||||
Download file
If the slide opens in your browser, select "File > Save As" to save it.
